Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Bladder cancer; Brain metastases; Urogenital cancer
- Focus Therapeutic Use
- 08 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 31 May 2019 Planned primary completion date changed from 20 Dec 2018 to 20 Dec 2019.
- 28 Feb 2018 Status changed from recruiting to active, no longer recruiting.